

Supplementary Figure S6. Subgroup analysis of PFS by tTMB for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of events. BEP, biomarker-evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; ITT, intention-to-treat; mut/Mb, mutations per megabase; PFS, progression-free survival; T, tremelimumab; tTMB, tissue tumor mutational burden.

